Recent News

• 12.06.2025 - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
• 11.03.2025 - Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
• 10.24.2025 - Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
• 10.22.2025 - Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
• 10.05.2025 - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
• 10.05.2025 - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
• 10.05.2025 - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 8-K Current report
• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.24.2025 - 8-K Current report
• 10.24.2025 - EX-99.1 EX-99.1
• 10.20.2025 - 8-K Current report
• 10.20.2025 - EX-99.1 EX-99.1